Abivax S.A.
NASDAQ:ABVXBiotechnology
-$0.62 today
- Market cap
- $7.34B
- Beta
- -0.20
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$4.83
Volume 1.19M
Average 1.59M
ABVX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Abivax S.A.NASDAQ: ABVX
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses remains negative
Q2 FY2026 other income / expenses was -€39.4M, compared with -€1.92M a year earlier.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
EUR · from the income statement
- Latest · FY2025
- (84.2M) EUR
- Year-over-year change
- -2484.3%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (84.2M) | -2484.3% |
| FY2024 | 2024-12-31 | (3.26M) | +84.0% |
| FY2023 | 2023-12-31 | (20.36M) | -597.2% |
| FY2022 | 2022-12-31 | 4.1M | +489.4% |
| FY2021 | 2021-12-31 | (1.05M) | — |
Other Income / Expenses vs competitors
How ABVX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2484.3% is the lowest of 11, against a peer median of -56.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $34M USD | +6.3% | +33.1% | 29.1% | |
| LTM Aug 2026 | $18.56M USD | -20.1% | +84.3% | 2.6% | |
| LTM Mar 2026 | $10.82M USD | -0.5% | +57.2% | 129.3% | |
| LTM Mar 2026 | $8.58M USD | -44.7% | +38.6% | — | |
| LTM Mar 2026 | $1.13M USD | +25.3% | — | — | |
| LTM Mar 2026 | -$5.41M USD | -104.4% | — | 9176.3% | |
| LTM Sep 2026 | -$13.69M USD | -121.2% | +303.0% | 15.1% | |
| LTM Mar 2026 | -$19.72M USD | -255.1% | — | 9.1% | |
| LTM Mar 2026 | -$67.43M USD | -67.3% | — | 29.0% | |
| FY2025 | -€84.2M EUR | -2484.3% | — | — | |
| FY2025 | -€211.38M EUR | -144.8% | — | 4715.1% | |
| Peer median (excluding ABVX) | — | -56.0% | +57.2% | 29.0% | |
Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 45.52M | 50.76M | 0 | 0 | 0 |
| Gross Profit | (45.52M) | (50.76M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.78M | 48.3M | 103.18M | 146.53M | 177.76M |
| Selling, General & Admin | 5.58M | 7.49M | 28.82M | 38.9M | 72.87M |
| Operating Expenses | (4.12M) | 14.07M | 127.38M | 172.98M | 246.06M |
| Depreciation & Amortization | 302K | 485K | 707K | 1.1M | 1.07M |
| EBITDA | (38.59M) | (53.32M) | (133.21M) | (162.71M) | (300.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (41.4M) | (64.84M) | (127.38M) | (172.98M) | (246.06M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 2.77M | 8.96M | 5.75M |
| Interest Expense | 3.56M | 6.94M | 13.83M | 12.43M | 28.48M |
| Other Income / Expenses | (1.05M) | 4.1M | (20.36M) | (3.26M) | (84.2M) |
| Income Before Tax | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (330.25M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 5.85M |
| Net Income | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (336.1M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.75) | (3.18) | (3.43) | (2.80) | (4.65) |
| EPS (Diluted) | (2.75) | (3.18) | (3.43) | (2.80) | (4.65) |
| Weighted Avg Shares | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
| Weighted Avg Shares (Diluted) | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
Abivax S.A.
NASDAQ:ABVX
Intrinsic Alpha fair value
Locked
Current Price
$83.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.